Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: The patients (n = 40) were evenly distributed between the two treatment groups, and the baseline demographics of the two groups were similar. The follow-up varied from 8 to 65 weeks (median 24 weeks). Compared with patients receiving placebo, those receiving zoledronic acid had a lower mean incidence of SREs (2.05 +/- 1.0 vs. 0.95 +/- 0.9, respectively), and a larger proportion did not experience an on-study SRE (2 vs. 8 patients, respectively). Zoledronic acid also prolonged the median time to first SRE compared with the placebo (16 vs. 8 weeks, respectively). Multiple event analysis of SREs revealed that zoledronic acid decreased the risk of SRE development by 59% (hazard ratio 0.413). Zoledronic acid also increased the 1-year survival rate compared with placebo (36.3 +/- 11.2 vs. 0%, respectively). Zoledronic acid was generally well tolerated in our patient population. CONCLUSIONS:
|
Authors | Mohamed S Zaghloul, Rimoun Boutrus, Hisham El-Hossieny, Yasser Abdel Kader, Inas El-Attar, Mohamed Nazmy |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 15
Issue 4
Pg. 382-9
(Aug 2010)
ISSN: 1437-7772 [Electronic] Japan |
PMID | 20354750
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Zoledronic Acid
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage)
- Bone Density Conservation Agents
(administration & dosage)
- Bone Neoplasms
(complications, drug therapy, mortality, secondary)
- Diphosphonates
(administration & dosage)
- Drug Administration Schedule
- Egypt
- Female
- Fractures, Bone
(etiology, prevention & control)
- Humans
- Hypercalcemia
(etiology, prevention & control)
- Imidazoles
(administration & dosage)
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Pain
(etiology, prevention & control)
- Placebo Effect
- Prospective Studies
- Risk Assessment
- Risk Factors
- Spinal Cord Compression
(etiology, prevention & control)
- Time Factors
- Treatment Outcome
- Urinary Bladder Neoplasms
(drug therapy, mortality, pathology)
- Zoledronic Acid
|